Lutz Wollin - Concepedia

Author

Lutz Wollin

Boehringer Ingelheim (Germany)ORCID

Also Known As

L Wollin, L. Wollin, LUTZ WOLLIN, Lutz Wollin

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Inserm University of Konstanz Université de Rennes Centre Hospitalier Universitaire de Rennes

About

Lutz Wollin is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacology, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	688
2	Allergy	4	4	149
3	Health Sciences	2	2	128
4	Engineering	1	1	129
5	Public Health	1	1	16

Lutz Wollin

Publications

Citations

H-Index

Page 1

	Year	Citations
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Journal of Pharmacology and Experimental Therapeutics	2014	610
In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 Inhibitor Daniela S. Bundschuh, Manfrid Eltze, Johannes Barsig, Journal of Pharmacology and Experimental Therapeutics	2001	237
Roflumilast Fully Prevents Emphysema in Mice Chronically Exposed to Cigarette Smoke Piero A. Martorana, Rolf Beume, Monica Lucattelli, American Journal of Respiratory and Critical Care Medicine	2005	192
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis Jingang Huang, Christian Beyer, Katrin Palumbo‐Zerr, Annals of the Rheumatic Diseases	2015	189
Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis Jingang Huang, Christiane Maier, Yun Zhang, Annals of the Rheumatic Diseases	2017	181
Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic Asthma Rakesh Kumar, Cristan Herbert, Paul S. Thomas, Journal of Pharmacology and Experimental Therapeutics	2003	148
Effects of nintedanib on the microvascular architecture in a lung fibrosis model Maximilian Ackermann, Yong Oock Kim, Willi L. Wagner, Angiogenesis MechanobiologyAntifibrotic TherapyFibrosisEngineeringPulmonary Circulation	2017	129
BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis Franziska Herrmann, Christian Heßlinger, Lutz Wollin, Frontiers in Pharmacology	2022	108
Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD Lutz Wollin, Michael Pieper Pulmonary Pharmacology & Therapeutics InflammationAnti-inflammatoryInflammatory Lung DiseaseAllergyMedicine	2010	99
An improved setup for the isolated perfused rat lung Stefan Uhlig, Lutz Wollin Journal of Pharmacological and Toxicological Methods Lung DepositionPulmonary CirculationPhysiologyBiomedical EngineeringImproved Setup	1994	87

Page 1